Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A. D. Manazza
Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC)
Current Cancer Drug Targets
Cancer Research
Drug Discovery
Oncology
Pharmacology
Related publications
The Human Equilibrative Nucleoside Transporter Protein1 (Hent1) Is a Predict /Prognostic Factor in Resected Pancreatic Cancer Patients
Biomedical Journal of Scientific & Technical Research
The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated With Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma
Clinical Cancer Research
Cancer Research
Oncology
Biweekly Cisplatin and Gemcitabine in Patients With Advanced Biliary Tract Cancer
International Journal of Cancer
Cancer Research
Oncology
Mutation of Trp29of Human Equilibrative Nucleoside Transporter 1 Alters Affinity for Coronary Vasodilator Drugs and Nucleoside Selectivity
Biochemical Journal
Biochemistry
Cell Biology
Molecular Biology
Chimeric Constructs Between Human and Rat Equilibrative Nucleoside Transporters (hENT1 and rENT1) Reveal hENT1 Structural Domains Interacting With Coronary Vasoactive Drugs
Journal of Biological Chemistry
Biochemistry
Cell Biology
Molecular Biology
A Nomogram to Predict Overall Survival for Biliary Tract Cancer
Cancer Management and Research
Oncology
Histological Complete Response in a Patient With Advanced Biliary Tract Cancer Treated by Gemcitabine/Cisplatin/S-1 Combination Chemotherapy: A Case Report
Molecular and Clinical Oncology
Cancer Research
Oncology
A Multicenter Phase II Study of S-1 for Gemcitabine-Refractory Biliary Tract Cancer
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Identification of TIGAR in the Equilibrative Nucleoside Transporter 2-Mediated Response to Fludarabine in Chronic Lymphocytic Leukemia Cells
Haematologica
Hematology
